SI-BONE posts Q3 2022 record revenue of $26.4M, up 19% YoY; guides FY22 revenue $104-105M

SI-BONE, Inc.

2022-Q3 EPS reported -$1.47 revenue$74,456,000

Worldwide revenue $26.4M (+19% YoY); U.S. revenue $24.6M (+21% YoY).
Gross margin 84% vs 89% YoY, pressured by product mix, lower ASPs, and higher freight.
Net loss $14.2M ($0.41/share) vs $15.9M ($0.48/share) in prior year.
FY2022 revenue guidance raised to $104-105M (16-17% growth); implies Q4 of $29.5-30.5M.
Over 800 U.S. active surgeons (+27% YoY); CMS finalized ~26-33% Medicare facility fee hike for 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SI-BONE, Inc. reported the quarter ended September 30, 2022 results: revenue $26.4 million, net income $14.2 million, EPS $0.41 per diluted share.

Period: the quarter ended September 30, 2022
Revenue: $26.4 million
Net income: $14.2 million
EPS: $0.41 per diluted share
Result: reported results

Exact text from the filing

musculoskeletal disorders of the sacropelvic anatomy, today reported financial results for the quarter ended September 30, 2022. Recent Highlights • Record world wide revenue of $26.4 million for the third quarter 2022, representing approximately 19% increase over the corresponding period in 2021 • Record U.S. revenue of $24.6 million for the third quarter 2022,

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

SI-BONE, Inc. filing history →

Source: SEC EDGAR

accession 0001459839-22-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.